Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases


Realizing the full potential of human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs) requires efficient methods for genetic modification. However, techniques to generate cell type–specific lineage reporters, as well as reliable tools to disrupt, repair or overexpress genes by gene targeting, are inefficient at best and thus are not routinely used. Here we report the highly efficient targeting of three genes in human pluripotent cells using zinc-finger nuclease (ZFN)–mediated genome editing. First, using ZFNs specific for the OCT4 (POU5F1) locus, we generated OCT4-eGFP reporter cells to monitor the pluripotent state of hESCs. Second, we inserted a transgene into the AAVS1 locus to generate a robust drug-inducible overexpression system in hESCs. Finally, we targeted the PITX3 gene, demonstrating that ZFNs can be used to generate reporter cells by targeting non-expressed genes in hESCs and hiPSCs.


Gene targeting by homologous recombination in hESCs has proven difficult, and since the derivation of the first hESCs more than 10 years ago, only a few reports have described successful gene targeting1,2,3,4,5,6,7,8,9. These studies illustrate the utility of genetically modifying hESCs by gene targeting, but a general approach to manipulate the hESC genome is still lacking. Recently, a technique based on the introduction of DNA double-strand breaks by site-specific ZFNs to facilitate homologous recombination has been used to target endogenous genes in human cells10,11. A ZFN is generated by fusing the FokI nuclease domain to a DNA recognition domain composed of engineered C2H2 zinc-finger motifs that specify the genomic DNA binding site for the chimeric protein (Fig. 1a). Upon binding of two such fusion proteins at adjacent genomic sites, the nuclease domains dimerize, become active and cut the genomic DNA. When a donor DNA that is homologous to the target on both sides of the double-strand break is provided, the genomic site can be repaired by homology-directed repair, allowing the incorporation of exogenous sequences placed between the homologous regions12,13. This technique, also called 'genome editing', has been applied in systems not easily amenable to genetic modifications, such as zebrafish, plants and rats14,15,16,17,18,19, and has also been used to edit the CCR5 locus in hESCs13.

Figure 1: Targeting of OCT4 in hESCs using ZFNs.

(a) Schematic overview depicting the targeting strategy for the OCT4 locus. Red boxes, probes used for Southern blot analysis; blue boxes, exons of OCT4; arrows, genomic site cut by the respective ZFN pair. Shown above is a schematic of the donor plasmid design. Donor plasmids were created corresponding to the cleavage location of the three ZFN pairs and carried roughly 700-bp regions of homology to the OCT4 sequence. SA-eGFP, splice acceptor–eGFP sequence; 2A, self-cleaving peptide sequence; PURO, puromycin resistance gene; polyA, polyadenylation sequence. Inset at upper left is a cartoon of two ZFNs binding at a specific genomic site (yellow), leading to dimerization of the FokI nuclease domains. (b) Southern blot analysis of BG01 cells targeted with the indicated ZFN pairs using the corresponding donor plasmids. Genomic DNA was either digested with EcoRI and hybridized with the external 3′ probe or digested with SacI and hybridized with the external 5′ probe or internal eGFP probe. Correctly targeted clones without additional integrations are indicated in red. Fragment sizes: for 5′ probe and eGFP probe, wt, 6.4 kb, targeted, 8.4 kb; for 3′ probe, wt, 7.1 kb, targeted, 9.1 kb. (c) Immunofluorescence staining of BG01 cells targeted with the indicated ZFN pairs using the corresponding donor plasmids. Cells were stained for the pluripotency markers OCT4, NANOG, SOX2, Tra-1-60 and SSEA4. (d) Hematoxylin and eosin staining of teratoma sections generated from BG01 cells targeted with the indicated ZFN pairs and the corresponding donor plasmids. (e) Western blot analysis for the expression of OCT4 and eGFP in BG01 wild-type (wt) cells and BG01 cells targeted with the indicated ZFN pairs using the corresponding donor plasmids. Cell extracts were derived from either undifferentiated cells (ES) or in vitro–differentiated fibroblast-like cells (Fib.)

We used the locus encoding the pluripotency-associated gene OCT4 (also known as POU5F1)—one of the few genes that has been successfully targeted in hESCs6—to compare the efficiency of ZFN-mediated gene targeting in hESCs with that of conventional homologous recombination. We designed four ZFN pairs that recognize unique sequences in the first intron of the OCT4 gene (Fig. 1a, Supplementary Fig. 1 and Supplementary Table 1) and generated targeting donor constructs with short homology arms for the three most active ZFNs pairs. Correct targeting of these donor constructs containing a splice acceptor (SA) followed by an enhanced green fluorescent protein (eGFP)-2A-puromycin cassette (2A is a self-cleaving peptide sequence) results in the expression of two proteins—a fusion protein comprising the first 132 amino acids of human OCT4 fused to eGFP (OCT4EX1-eGFP) and puromycin N-acetyltransferase—both under the control of the endogenous OCT4 promoter. Southern blot analysis using external probes 3′ and 5′ to the donor homology regions and an internal probe against eGFP revealed that for ZFN pair #1, 40 out of 42 individual cell lines established from puromycin-resistant clones were correctly targeted (efficiency >94%; Fig. 1b and Table 1). ZFN pair #2 had a correct targeting frequency of 36–53% (Table 1). Of the remaining clones, most were correctly targeted in the OCT4 locus but also carried additional nonhomologous integrations (Fig. 1b and Table 1). ZFN pair #3 had the lowest targeting efficiency and generated only a few puromycin-resistant clones, some of which were correctly targeted. OCT4EX1-eGFP-targeted cells maintained a pluripotent state, as indicated by the expression of the pluripotency markers OCT4, NANOG, SOX2, Tra-1-60 and SSEA4 (Fig. 1c) and their ability to form cell types originating from all three developmental germ layers in teratoma-formation assays (Fig. 1d).

Table 1 Summary of targeting experiments

We detected expression of the OCT4EX1-eGFP fusion protein in hESCs by western blotting with antibodies against OCT4 and eGFP (Fig. 1e). When targeted hESCs were differentiated into fibroblasts, no OCT4EX1-eGFP protein was detected (Fig. 1e) and the cells regained puromycin sensitivity, demonstrating the validity of the reporter expression. Unexpectedly, clones targeted by ZFN pair #1 showed significantly lower OCT4EX1-eGFP protein expression than clones targeted by ZFN pair #2, as indicated by western blot and FACS analysis (Fig. 1e and Supplementary Fig. 2). Additionally, hESCs targeted by ZFN pair #1 tolerated only puromycin concentrations of 0.5 μg/ml, whereas those targeted by ZFN pair #2 could be maintained in up to 2 μg/ml puromycin (data not shown), suggesting that the former had lower expression of puromycin N-acetyltransferase. One possible explanation of this finding is that the integration of the SA-eGFP-2A-puromycin cassette occurred very close to the splice donor of the first coding exon of OCT4 (separated by 102 bp), perhaps impeding splicing efficiency and resulting in reduced OCT4EX1-eGFP expression.

Approaches to expressing transgenes in hESCs include random integration of expression vectors and the insertion of an expression construct with isogenic vector arms into the ROSA26 locus4 by homologous recombination. However, unpredictable position effects or low targeting frequencies have limited the utility of these methods. To develop a highly efficient and robust expression system, we used ZFN technology to target the AAVS1 locus located on chromosome 19, encoding the PPP1R12C gene, which is ubiquitously expressed. This well-characterized locus has been previously shown to allow stable and long-term expression of transgenes in multiple cell types, including hESCs20. To target the first intron of PPP1R12C, we used a ZFN pair that generates a double-strand break at its target locus in hESCs (Supplementary Fig. 1b and Supplementary Table 1) and can be used to efficiently insert transgenes into this locus in transformed human cell lines (R.C. DeKelver, V.M. Choi, E.A. Moehle, D.E. Paschon, J.C. Miller, F.D. Urnov et al., unpublished results).

Two constructs with identical short homology arms were used to target the AAVS1 locus: (i) a gene-trap vector for the PPP1R12C promoter containing a SA-2A-puromycin selection cassette and (ii) a puromycin selection cassette driven from the phosphoglycerol kinase (PGK) promoter (Fig. 2a). As indicated by Southern blot analysis, both vectors generated 50% puromycin-resistant clones that had correctly targeted insertions on one or both alleles with no additional random integrations (Fig. 2b, Table 1 and Supplementary Fig. 3). The ability to target genes with vectors using a selection cassette controlled by an exogenous promoter is important for targeting genes not expressed in hESCs, as demonstrated below for PITX3. All tested AAVS1-targeted hESCs, including homozygous targeted clones, retained a normal karyotype (n = 4) (Supplementary Fig. 4a) and remained pluripotent as determined by immunofluorescence staining for pluripotency markers (Supplementary Fig. 4b) and teratoma-formation assays (Supplementary Fig. 4c). hiPSCs21 could be targeted with efficiency similar to that for hESCs (Supplementary Fig. 5a,b and Table 1)

Figure 2: Targeting of the AAVS1 locus using ZFNs.

(a) Schematic overview depicting the targeting strategy for the PPP1R12C gene in the AAVS1 locus. Red boxes, probes used for Southern blot analysis; blue boxes, first 3 exons of PPP1R12C; arrow, genomic site cut by the AAVS1 ZFNs. Donor plasmids used to target the locus are shown above. SA-PURO, splice acceptor sequence followed by a 2A self-cleaving peptide sequence and the puromycin resistance gene; pA, polyadenylation sequence; PGK, human phophoglycerol kinase promoter; PURO, puromycin resistance gene. (b) Southern blot analysis of BG01 cells targeted with the indicated donor plasmids using the AAVS1 ZFNs. Genomic DNA was digested with SphI and hybridized with the 32P-labeled external 3′ probe or the internal 5′ probe. Fragment sizes for PGK-PURO: 5′ probe: wt, 6.5 kb, targeted, 4.2 kb; 3′ probe: wt, 6.5 kb, targeted, 3.7 kb. Fragment sizes for SA-PURO: 5′ probe: wt, 6.5 kb, targeted, 3.8 kb; 3′ probe: wt, 6.5 kb, targeted, 3.7 kb. (c) Southern blot analysis of BG01 cells targeted with an AAVS1 donor plasmid containing a CAGGS-driven eGFP cassette using the AAVS1 ZFNs. Genomic DNA was digested with SphI and hybridized with the 32P-labeled external 3′ probe or the internal 5′ probe. Fragment sizes for CAGGS-GFP: 5′ probe: wt, 6.5 kb, targeted, 3.8 kb; 3′ probe: wt, 6.5 kb, targeted, 6.9 kb. (d) Phase-contrast picture and fluorescence imaging of eGFP in heterozygous or homozygous BG01 clones targeted with an AAVS1 donor plasmid containing a CAGGS-driven eGFP cassette and the AAVS1 ZFNs. (e) Schematic overview depicting the targeting strategy for the PPP1R12C gene in the AAVS1 locus with a donor construct containing a DOX-inducible TetO-eGFP. Red boxes, probes used for Southern blot analysis; blue boxes, first three exons of the PPP1R12C gene in the AAVS1 locus; arrows, genomic site cut by the ZFNs. Donor plasmids used to target the AAVS1 locus are shown above. SA-PURO, splice acceptor sequence followed by a 2A self-cleaving peptide sequence and the puromycin resistance gene; pA, polyadenylation sequence; TetO, tetracycline response element. (f) Phase-contrast picture and fluorescence imaging of eGFP in BG01 cells either heterozygous (AAVS1 TetO-GFP+/−) or homozygous (AAVS1-TetO-GFP+/+) for the DOX-inducible eGFP cassette targeted to the AAVS1 locus. Cells were transduced with a M2rtTA lentivirus to render them DOX responsive. Panel shows colonies before (top) and after FACS-assisted subcloning in the presence of DOX (bottom). (g) Southern blot analysis of BG01cells targeted with the indicated donor plasmids using the AAVS1 ZFNs. Genomic DNA was digested with SphI and hybridized with the 32P-labeled external 3′ probe or the internal 5′ probe. Fragment sizes: 5′ probe: wt, 6.5 kb, targeted, 3.8 kb; 3′ probe: wt, 6.5 kb, targeted, 5.1 kb. (h) FACS analysis of AAVS1-TetO-GFP+/− and AAVS1-TetO-GFP+/+ subclones for eGFP expression at different concentrations of DOX. BG01 cells, targeted cells before M2rtTA infection, and subcloned DOX-responsive cell lines cultured at different concentrations of DOX were analyzed. All cells were co-stained and analyzed for SSEA4 expression to exclude SSEA4-negative feeder cells from the analysis.

To develop a transgenic overexpression system, we targeted to the AAVS1 locus a donor plasmid expressing eGFP under the control of the constitutively active CAGGS promoter (Fig. 2c). HESCs targeted with this construct showed persistent and uniform eGFP expression (Fig. 2d). To generate an inducible expression system, an AAVS1 donor plasmid containing a minimal cytomegalovirus (CMV) promoter and a tetracycline response element driving the eGFP cDNA (TetO-eGFP) was targeted into the AAVS1 locus in either the same or the opposite orientation as the PPP1R12C gene (Fig. 2e). ZFN-mediated targeting of BG01 cells with these donor plasmids yielded correctly targeted heterozygous (AAVS1-TetO-eGFP+/−) and homozygous (AAVS1-TetO-eGFP+/+) hESCs (Fig. 2f,g) with high efficiencies similar to those described above (TetO-FW, 47%; TetO-BW, 40%; Table 1). Correctly targeted hESCs were transduced with a lentivirus carrying the M2rtTA reverse transactivator to render the cells doxycycline (DOX) responsive. In agreement with previously reported lentiviral transduction efficiencies of hESCs, approximately 10% of the cells showed eGFP expression after the addition of DOX (Fig. 2f). To test DOX-inducible eGFP expression, we withdrew DOX from the cultures for varying lengths of time and found that eGFP fluorescence became undetectable 7 d after DOX withdrawal (Supplementary Fig. 6). We next established cell lines that showed limited silencing of the M2rtTA viral transgene by single-cell subcloning (Fig. 2f). FACS analysis of these cell lines, cultured under different DOX concentrations, revealed a dose-dependent relationship between DOX concentration and eGFP expression (Fig. 2h). These experiments showed that eGFP expression was dependent on DOX addition and on the presence of M2rtTA, indicating tight regulation of the eGFP expression cassette when integrated into the AAVS1 locus. There were no apparent differences between the two orientations of the TetO-eGFP cassette.

Finally, we tested whether ZFNs could be used to modify genes that are not expressed in hESCs and hiPSCs by targeting the first exon of PITX3. PITX3 is a transcription factor expressed in some differentiated cell types, such as dopaminergic neurons, but not in hESCs. To generate a PITX3 reporter, we designed a targeting construct in which the PITX3 open reading frame was joined after amino acid 32 to the gene for eGFP followed by a polyadenylation signal and a loxP-flanked PGK-puromycin cassette (Fig. 3a). Coelectroporation of the donor plasmid with the PITX3 ZFN pair #2 (Supplementary Fig. 7) into hESCs or two hiPSC21 lines resulted in correctly targeted clones with efficiencies of 11% for hESCs and 8% for iPSCs, as determined by Southern blot analysis (Fig. 3b,c and Table 1). All tested hESC and hiPSC lines targeted in the PITX3 locus maintained a normal karyotype (hESC n = 3, hiPSC n = 3). The PGK-puromycin cassette was subsequently removed by transient expression of Cre recombinase (Fig. 3b). The relatively high targeting efficiency in hESCs and hiPSCs demonstrates that ZFN-mediated gene targeting is a robust tool for modifying genes not expressed in hECS so as to generate cell type–specific reporter systems. ZFN-mediated gene targeting therefore has the potential to overcome one of the main obstacles in hESC and hiPSC research.

Figure 3: Targeting of PITX3 in hESCs and hiPSCs using ZFNs.

(a) Schematic overview depicting the targeting strategy for the PITX3 gene. Red boxes, probes for Southern blot analysis; blue boxes, first exons of PITX3; arrows, genomic site cut by ZFN pair #2. Donor plasmids used to target the PITX3 locus are shown above; these contained 5′ and 3′ homologous sequences of approximately 800 bp flanking the predicted ZFN pair #2 target site. eGFP, enhanced green fluorescent protein; PGK, human phophoglycerol kinase promoter; PURO, puromycin resistance gene, loxP, loxP sites; pA, polyadenylation sequence. Two constructs that differed only in the orientation of this selection cassette with respect to PITX3 were successfully used to target PITX3 (see also Table 1). (b) Southern blot analysis of BG01 cells targeted with the indicated donor plasmid using the PITX3 ZFNs. Right, Southern blot analysis of clones in which the PGK-PURO cassette was removed by transient expression of Cre recombinase. Genomic DNA was digested with HindIII and probed with 32P-labeled external 5′ probe or the internal 3′ probe. Fragment sizes are: 5′ probe: wt, 8.8 kb, targeted, 7.4 kb, Δ-PGK-PURO, 10.5 kb; 3′ probe: wt, 8.8 kb, targeted, 4.3 kb. (c) Southern blot analysis of the hiPSCs targeted with the indicated donor plasmids using the PITX3 ZFNs. Genomic DNA was digested and probed as in b. Fragment sizes: 5′ probe: wt, 8.8 kb, targeted, 7.4 kb; 3′ probe: wt, 8.8 kb, targeted, 4.3 kb.

A potential limitation of the ZFN targeting approach is off-target DNA breaks induced at related sequences elsewhere in the genome, which may cause unpredictable genotoxic effects. Although our Southern blot analysis using internal and external probes excluded additional integrations and confirmed the clonality of targeted clones, these analyses do not detect ZFN-mediated double-strand breaks and error-prone repair elsewhere in the genome. To examine off-target cleavage, we determined the DNA binding specificity for all ZFNs by SELEX (Supplementary Table 2), which made it possible to identify the most probable off-target cleavage sites on a genome-wide basis (Supplementary Figs. 8a, 9a, 10a and 11a). Using the Cel-1 assay, we quantified the frequency of nonhomologous end joining (NHEJ)–mediated alterations in up to ten potential off-target sites in clones generated by four different ZFNs used in this study (Table 1b and Supplementary Figs. 8b,c, 9b,c, 10b,c and 11b,c). In analyzing 46 genomic loci, we detected one NHEJ alteration at one genomic site in one of four PITX3 clones (Table 1 and Supplementary Fig. 9b–d); all the other putative off-target sites for all the ZFNs in all the clones were wild type. Finally, we determined in heterozygously targeted clones the frequency of NHEJ alterations on the allele that did not carry an integrated transgene. This frequency was 1/18 for the PITX3 clones and 1/12 for the OCT4 clones carrying a disruption on the other allele (Table 1b); in all other cases, the other allele remained wild type. To ensure that a functional wild-type allele will be present in heterozygously targeted clones, the recognition sequence of the ZFNs can be designed to recognize intron sequences, as was done for the OCT4 and AAVS1 loci.

A recent study22 described the use of ZFNs to disrupt the PIGA gene in hESCs and hiPSCs through the insertion of a drug-resistance marker; this work, together with our data on targeting five distinct loci in three different genes, demonstrates the utility of ZFNs for disrupting genes in human pluripotent stem cells. In addition, we have engineered both the PITX3 locus, which is not expressed in hESCs, and the OCT4 locus to report on cell fate and the AAVS1 locus to be a 'safe harbor' for an inducible transgene, illuminating the range of genotypes that can be generated with ZFNs. We also note that, to ensure the uniqueness of our intended targets within the human genome, we relied on ZFNs containing 4–6 zinc fingers, which recognize composite sites of 24–36 bp.

ZFN-mediated gene targeting requires only relatively short targeting arms (for AAVS1, about 500 bp for each arm), facilitating the generation of targeting constructs to achieve site-specific integration of exogenous genes whose expression can be controlled by constitutively active, inducible or tissue-specific promoters. This is in contrast to targeting of genes such as OCT4 by conventional homologous recombination, which has been shown to result in targeting efficiencies of 20% and 40% when isogenic targeting arms of 7.9 and 12.8 kb, respectively, were used6. Moreover, the use of short targeting arms combined with ZFN technology results in high targeting efficiencies even when the same donor plasmids are used in genetically different cell lines, eliminating the need to construct isogenic targeting vectors. Although it is possible that not all nonexpressed genes can be targeted by ZFNs, the extraordinary flexibility available in designing zinc-finger binding motifs23,24 will likely allow targeting of a substantial fraction of genes. Thus, this approach should be useful in generating genetic tools to study cell fate decisions and cell type–specific reporter systems to improve hESC differentiation protocols.

Note: Supplementary information is available on the Nature Biotechnology website.


Cell culture.

Cell culture techniques have been described previously21. HiPSCs and the hESC line BG01 (NIH code BG01; BresaGen, Inc.) were maintained on mitomycin C–inactivated mouse embryonic fibroblast (MEF) feeder layers in hESC medium (DMEM/F12 (Invitrogen) supplemented with 15% fetal bovine serum (FBS) (HyClone), 5% KnockOut Serum Replacement (Invitrogen), 1 mM glutamine (Invitrogen), 1% nonessential amino acids (Invitrogen), 0.1 mM β-mercaptoethanol (Sigma) and 4 ng/ml FGF2 (R&D Systems)). Cultures were passaged every 5–7 d either manually or enzymatically with collagenase type IV (Invitrogen; 1.5 mg/ml). In order to perform FACS analysis of OCT4-eGFP clones in the absence of MEF feeder cells, hESCs were passaged onto Matrigel-coated plates in mTeSR medium (Stemcell Technologies). Karyotyping analysis was performed by Cell Line Genetics.

ZFN design and ZFN expression plasmids.

ZFNs against the human OCT4, AAVS1 and PITX3 loci were designed using an archive of prevalidated two-finger modules exactly as described in published work10,16,25; complete sequences of the ZFNs, which carried obligate heterodimer forms of the FokI endonuclease26, are provided in Supplementary Table 1. The ZFNs were designed and tested at Sangamo BioSciences for the purpose of disruption of their intended target loci by transient transfection into K562, HeLa and HEK293 cells, followed by Surveyor (Cel-1) endonuclease–based measurement of NHEJ at the target locus exactly as described26,25 (primers used in Cel-1 analysis are provided in the Supplementary Table 2); the ZFN expression constructs were then provided to the Jaenisch laboratory.

Targeting of hESCs and hiPSCs using ZFN-mediated homologous recombination.

hESCs and hiPSCs were cultured in rho kinase (ROCK) inhibitor (Calbiochem; Y-27632) 24 h before electroporation. Cells were harvested using 0.25% trypsin/EDTA solution (Invitrogen) and 1 × 107 cells resuspended in PBS were electroporated, if not otherwise indicated, with 40 μg of donor plasmids (designed and assembled by D.H. and F.S.) and 5 μg of each ZFN-encoding plasmid (Gene Pulser Xcell System, Bio-Rad; 250 V, 500 μF, 0.4-cm cuvettes3). Cells were subsequently plated on MEF feeder layers (DR4 MEFs for puromycin selection) in hESC medium supplemented with ROCK inhibitor for the first 24 h. Individual colonies were picked and expanded after puromycin selection (0.5 μg/ml) 10–14 d after electroporation.

Experimental genome-wide evaluation of ZFN action.

A double-strand break persistently induced by designed ZFNs is repaired by NHEJ, an error-prone process27 that generates small insertions and deletions at the site of the break28. This feature has been extensively used to profile the consequences of ZFN-driven editing on the target genome15,16,17,25. In the present work, such genotyping was performed essentially as described previously16,25. First, the consensus target for each ZFN was experimentally determined by SELEX as described25 under conditions known to yield a biologically relevant consensus site for C2H2 ZFPs29. These studies yielded the targets provided in Supplementary Table 3. Next, the human genome was searched for candidate off-target sites that provided the best match to the experimentally determined base-frequency matrices obtained from the SELEX studies. In performing this step, we allowed ZFN site pairings with 5 or 6 bp between individual targets, in order to reflect the ability of our designed ZFNs to cleave equally well at these two spacings. Likewise, we also allowed an optional gap of 1 bp between the ninth and tenth bases of Oct-4 ZFN #1-R in order to reflect the binding characteristics of a longer flexible linker between the second and third fingers of this protein that allows binding to either target type. Finally, the experimentally determined base-frequency matrices for each ZFN pair were used to rank the potential off-target sites. For each ZFN target, the top-10-ranked off-target sites were then genotyped as follows. Four single cell–derived clones heterozygous for the transgene at the ZFN target site were chosen at random, genomic DNA was isolated, and every potential off-target site was amplified using 32 cycles of PCR with Accuprime Taq HiFi DNA polymerase (Invitrogen). The majority of the sites were then genotyped using the Surveyor endonuclease ('Cel-1'; Transgenomics) assay exactly as described26, with the following modification: to address the potential for biallelic homozygous disruption (which would yield no Cel-1 signal), an equal amount of PCR product amplified from control cells was added to that from the ZFN-edited clone. Following a denaturation-renaturation step and treatment with Cel-1 to cleave heteroduplexes formed from wild-type and mutated DNA strands, the reaction was resolved by 10% nondenaturing PAGE (Bio-Rad) in 1× TBE. One putative off-target site was found to be heterozygous for a SNP, precluding the use of the Cel-1 assay; it was genotyped by cloning (TopoTA; Invitrogen) and Sanger sequencing. In addition to the analysis of putative off-target sites, for each heterozygous clone, the nontransgenic allele of the ZFN target locus was genotyped by PCR (using primers shown in Supplementary Table 1), cloning and sequencing.

Fibroblast differentiation of OCT4-eGFP hESCs.

Embryoid body (EB)-induced differentiation was performed as previously described30. Briefly, hESC colonies were harvested using 1.5 mg/ml collagenase type IV (Invitrogen), separated from the MEF feeder cells by gravity, gently triturated and cultured for 7 d in nonadherent suspension culture dishes (Corning) in DMEM supplemented with 20% FBS. EBs were plated onto adherent tissue culture dishes and passaged according to primary fibroblast protocols using trypsin for at least four passages before the start of experiments.

Removal of PGK-PURO cassette by transient Cre-recombinase expression.

HESCs targeted in the PITX3 locus were cultured in ROCK inhibitor for 24 h prior to electroporation. Cells were harvested using 0.25% trypsin/EDTA solution (Invitrogen) and 1 × 107 cells resuspended in PBS were electroporated with pTurbo-Cre (40 μg; GenBank accession number AF334827) and pEGFP-N1 (10 μg; Clontech) as described previously3 (Gene Pulser Xcell System, Bio-Rad; 250 V, 500 μF, 0.4-cm cuvettes). Cells were subsequently plated on MEF feeder layers in hESC medium supplemented with ROCK inhibitor. Cre recombinase–expressing cells were enriched by FACS sorting (FACS-Aria; BD Biosciences) of a single-cell suspension for eGFP expressing cells 60 h after electroporation followed by replating at a low density in ROCK inhibitor–containing hESC medium. Individual colonies were picked 10–14 d after electroporation.

Lentiviral infection of hESCs.

The FUW-M2rtTA lentiviral vector has been described previously30. Vesicular stomatitis virus glycoprotein (VSVG)-coated lentiviruses were generated in 293 cells as described previously31. Briefly, culture medium was changed 12 h after transfection and virus-containing supernatant was collected 60–72 h after transfection. Viral supernatant was filtered through a 0.45-μm filter. This virus-containing supernatant was used to infect hESC aggregates that were separated from feeder cells by collagenase treatment and serial washes. Two consecutive infections in the presence of 2 μg/ml of polybrene were performed over a period of 12 h in suspension. hESC aggregates were replated after infection on feeder cells. Infection efficiencies were determined using FACS analysis for eGFP and SSEA4 (mouse monoclonal, Developmental Studies Hybridoma Bank) of cells cultured in the presence of DOX (Sigma-Aldrich; 2 μg/ml) for 2 d. To enrich for eGFP expressing cells, targeted and infected hESCs were FACS sorted as single-cell suspension 2 d after DOX induction in the presence of ROCK inhibitor (FACS-Aria; BD-Biosciences) and subsequently replated in the ROCK inhibitor–containing hESC medium. DOX-responsive GFP-expressing cell lines were isolated by manual picking of single colonies.

Teratoma formation and analysis.

HESCs were collected by collagenase treatment (1.5 mg/ml) and separated from feeder cells by subsequent washes with medium and sedimentation by gravity. HESC aggregates were collected by centrifugation, resuspended in 250 μl of PBS and injected subcutaneously in the back of severe combined immunodeficient (SCID) mice (Taconic). Tumors generally developed within 4–8 weeks, and animals were killed before tumor size exceeded 1.5 cm in diameter. Teratomas were isolated and fixed in formalin. After sectioning, teratomas were diagnosed on the basis of hematoxylin and eosin staining.


Cells were fixed in 4% paraformaldehyde in PBS and immunostained according to standard protocols using the following antibodies: SSEA4 (mouse monoclonal, Developmental Studies Hybridoma Bank); Tra-1-60 (mouse monoclonal, Chemicon International); hSOX2 (goat polyclonal, R&D Systems); Oct-3/4 (mouse monoclonal, Santa Cruz Biotechnology); hNANOG (goat polyclonal R&D Systems) and appropriate Molecular Probes Alexa Fluor dye–conjugated secondary antibodies (Invitrogen).


HESCs were collected by collagenase treatment (1.5 mg/ml)and separated from feeder cells by subsequent washes with medium and sedimentation by gravity. hESC-derived fibroblasts were collected by trypsinization. Cells were pelleted by centrifugation and washed with PBS and again collected by centrifugation. Cells were lysed in ice-cold buffer (50 mM Tris-HCl, pH 7.4, 20% glycerol, 1 mM EDTA, 150 mM NaCl, 0.5% Triton X-100, 0.02% SDS, 1 mM dithiothreitol, 2 mM phenylmethylsulfonyl fluoride, supplemented with proteinase inhibitor cocktail (Complete Mini, Roche). After 5 min on ice, 5 M NaCl was added to bring the final NaCl concentration to 400 mM. After 5 min on ice, an equal volume of ice-cold water was added and the lysate was mixed before immediate centrifugation in a microcentrifuge (14,000 rpm, 10 min). Protein concentration of the supernatant was determined by Bradford assay and 15 μg of protein was separated using 4–12% Bis-Tris gradient gels (Invitrogen). After transfer to PVDF membranes, blots were probed with antibodies to OCT4 (mouse monoclonal, Santa Cruz Biotechnology) or to GFP (Rbt pAB to GFP, Abcam ab290-50).

Southern blotting.

Genomic DNA was separated on a 0.7% agarose gel after restriction digests with the appropriate enzymes, transferred to a nylon membrane (Amersham) and hybridized with 32P-labeled random primer (Stratagene) probes.

Accession codes




  1. 1

    Thomson, J.A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145–1147 (1998).

    CAS  Article  Google Scholar 

  2. 2

    Urbach, A., Schuldiner, M. & Benvenisty, N. Modeling for Lesch-Nyhan disease by gene targeting in human embryonic stem cells. Stem Cells 22, 635–641 (2004).

    CAS  Article  Google Scholar 

  3. 3

    Costa, M. et al. A method for genetic modification of human embryonic stem cells using electroporation. Nat. Protoc. 2, 792–796 (2007).

    CAS  Article  Google Scholar 

  4. 4

    Irion, S. et al. Identification and targeting of the ROSA26 locus in human embryonic stem cells. Nat. Biotechnol. 25, 1477–1482 (2007).

    CAS  Article  Google Scholar 

  5. 5

    Suzuki, K. et al. Highly efficient transient gene expression and gene targeting in primate embryonic stem cells with helper-dependent adenoviral vectors. Proc. Natl. Acad. Sci. USA 105, 13781–13786 (2008).

    CAS  Article  Google Scholar 

  6. 6

    Zwaka, T.P. & Thomson, J.A. Homologous recombination in human embryonic stem cells. Nat. Biotechnol. 21, 319–321 (2003).

    CAS  Article  Google Scholar 

  7. 7

    Davis, R.P. et al. Targeting a GFP reporter gene to the MIXL1 locus of human embryonic stem cells identifies human primitive streak-like cells and enables isolation of primitive hematopoietic precursors. Blood 111, 1876–1884 (2008).

    CAS  Article  Google Scholar 

  8. 8

    Xue, H. et al. A targeted neuroglial reporter line generated by homologous recombination in human embryonic stem cells. Stem Cells 27, 1836–1846 (2009).

    CAS  Article  Google Scholar 

  9. 9

    Ruby, K.M. & Zheng, B. Gene targeting in a HUES line of human embryonic stem cells via electroporation. Stem Cells 27, 1496–1506 (2009).

    CAS  Article  Google Scholar 

  10. 10

    Urnov, F.D. et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435, 646–651 (2005).

    CAS  Article  Google Scholar 

  11. 11

    Carroll, D. Progress and prospects: zinc-finger nucleases as gene therapy agents. Gene Ther. 15, 1463–1468 (2008).

    CAS  Article  Google Scholar 

  12. 12

    Moehle, E.A. et al. Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases. Proc. Natl. Acad. Sci. USA 104, 3055–3060 (2007).

    CAS  Article  Google Scholar 

  13. 13

    Lombardo, A. et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat. Biotechnol. 25, 1298–1306 (2007).

    CAS  Article  Google Scholar 

  14. 14

    Cai, C.Q. et al. Targeted transgene integration in plant cells using designed zinc finger nucleases. Plant Mol. Biol. 69, 699–709 (2009).

    CAS  Article  Google Scholar 

  15. 15

    Meng, X., Noyes, M.B., Zhu, L.J., Lawson, N.D. & Wolfe, S.A. Targeted gene inactivation in zebrafish using engineered zinc-finger nucleases. Nat. Biotechnol. 26, 695–701 (2008).

    CAS  Article  Google Scholar 

  16. 16

    Doyon, Y. et al. Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat. Biotechnol. 26, 702–708 (2008).

    CAS  Article  Google Scholar 

  17. 17

    Shukla, V.K. et al. Precise genome modification in the crop species Zea mays using zinc-finger nucleases. Nature 459, 437–441 (2009).

    CAS  Article  Google Scholar 

  18. 18

    Townsend, J.A. et al. High-frequency modification of plant genes using engineered zinc-finger nucleases. Nature 459, 442–445 (2009).

    CAS  Article  Google Scholar 

  19. 19

    Geurts, A.M. et al. Knockout rats via embryo microinjection of zinc-finger nucleases. Science 325, 433 (2009).

    CAS  Article  Google Scholar 

  20. 20

    Smith, J.R. et al. Robust, persistent transgene expression in human embryonic stem cells is achieved with AAVS1-targeted integration. Stem Cells 26, 496–504 (2008).

    CAS  Article  Google Scholar 

  21. 21

    Soldner, F. et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136, 964–977 (2009).

    CAS  Article  Google Scholar 

  22. 22

    Zou, J. et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 5, 97–110 (2009).

    CAS  Article  Google Scholar 

  23. 23

    Pabo, C.O., Peisach, E. & Grant, R.A. Design and selection of novel Cys2His2 zinc finger proteins. Annu. Rev. Biochem. 70, 313–340 (2001).

    CAS  Article  Google Scholar 

  24. 24

    Klug, A. The discovery of zinc fingers and their development for practical applications in gene regulation. Proc. Jpn. Acad. 81, 87–102 (2005).

    CAS  Article  Google Scholar 

  25. 25

    Perez, E.E. et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 26, 808–816 (2008).

    CAS  Article  Google Scholar 

  26. 26

    Miller, J.C. et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat. Biotechnol. 25, 778–785 (2007).

    CAS  Article  Google Scholar 

  27. 27

    Valerie, K. & Povirk, L.F. Regulation and mechanisms of mammalian doublestrand break repair. Oncogene 22, 5792–5812 (2003).

    CAS  Article  Google Scholar 

  28. 28

    Bibikova, M., Golic, M., Golic, K.G. & Carroll, D. Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. Genetics 161, 1169–1175 (2002).

    CAS  PubMed  PubMed Central  Google Scholar 

  29. 29

    Phillips, C.M. et al. Identification of chromosome sequence motifs that mediate meiotic pairing and synapsis in C. elegans. Nat. Cell. Biol. 11, 934–942 (2009).

    CAS  Article  Google Scholar 

  30. 30

    Hockemeyer, D. et al. A drug-inducible system for direct reprogramming of human somatic cells to pluripotency. Cell Stem Cell 3, 346–353 (2008).

    CAS  Article  Google Scholar 

  31. 31

    Brambrink, T. et al. Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells. Cell Stem Cell 2, 151–159 (2008).

    CAS  Article  Google Scholar 

Download references


We thank R. Alagappan, P. Xu and E. Cook for technical support and J. Dausman, R. Flannery and D. Fu for their help with animal husbandry and processing of teratomas. We thank all the members of the Jaenisch laboratory for helpful discussions and comments on the manuscript. D.H. is a Merck Fellow of the Life Science Research Foundation. R.J. was supported by US National Institutes of Health grants R37-CA084198, RO1-CA087869 and RO1-HD045022: and by the Howard Hughes Medical Institute. Requests for ZFNs should be directed to F.D.U. (

Author information




D.H., F.S. and R.J. designed the experiments and wrote the paper. C.B. provided assistance with construct design and Southern blot analysis. Q.G. analyzed all teratomas. M.M. provided hESCs. J.C.M. and L.Z. designed the ZFNs, which were assembled and tested by R.C.D., G.E.K. and R.A. X.M. performed the SELEX experiments. E.A.B. and B.Z. genotyped ZFN-edited clones for off-target effects. F.D.U., E.J.R. and P.D.G. supervised the ZFN design, characterization and off-target analysis and helped analyze the data and write the paper. D.H. and F.S. performed all other experiments.

Corresponding author

Correspondence to Rudolf Jaenisch.

Ethics declarations

Competing interests

R.J. is an adviser to Stemgen and a cofounder of Fate Therapeutics. R.C.D., G.E.K., R.A., B.Z., X.M., J.C.M., L.Z., E.J.R., P.D.G. and F.D.U. are full-time employees of Sangamo BioSciences, Inc.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–11 and Supplementary Tables 1–3 (PDF 11269 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hockemeyer, D., Soldner, F., Beard, C. et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol 27, 851–857 (2009).

Download citation

Further reading


Quick links